Struggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. Source: BioSpace
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. Source: BioSpace
Iftach Seri previously served as Sun Pharmaceutical’s head of API. Source: BioSpace
A look at why a potential buyout of Acadia might not be as likely as some have suggested. Source: BioSpace
Shawver, a long-time industry veteran, will assume the role of president, CEO and director of Synthorx. Source: BioSpace
On Oct. 6, the FDA approved Flexion Therapeutics' Zilretta for osteoarthritis knee pain and is now in the middle of launching the drug and installing its commercial operations. Source: BioSpace
The company announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb’s 2017 Golden Tickets for LabCentral. Source: BioSpace
The safety profile of avelumab was consistent with that observed in the overall JAVELIN clinical development program. Source: BioSpace
J&J is balking at a plan to build a site in Britain due to concerns over the economy. Source: BioSpace
Gritstone Oncology is hanging a "help wanted" sign as the company looks to staff a new 43,000 square-foot manufacturing facility in Pleasanton, Calif. that will be the center of the…
AM-111 failed to meet its primary endpoint, although the company is putting a positive spin on it by noting it was effective in a subpopulation. Source: BioSpace